Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 6/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 11/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | THRB | P10828 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15043477 | 0.94 | RXFP1 (0.60) | RXFP1LMNATP53MEN1KMT2A | |
| SCHEMBL9912167 | 0.83 | LMNA (0.60) | RXFP1LMNATP53MEN1KMT2A | |
| SCHEMBL15043470 | 0.81 | GABRA5 (0.58) | RXFP1LMNATP53MEN1KMT2A | |
| SCHEMBL9910999 | 0.80 | RXFP1 (0.50) | RXFP1LMNATP53MEN1KMT2A | |
| SCHEMBL15043471 | 0.78 | POLB (0.48) | RXFP1LMNATP53MEN1KMT2A | |
| SCHEMBL24099252 | 0.78 | RXFP1 (0.60) | RXFP1LMNATP53MEN1KMT2A | |
| SCHEMBL30380917 | 0.78 | RXFP1 (0.60) | RXFP1LMNATP53MEN1KMT2A | |
| SCHEMBL9911002 | 0.77 | RXFP1 (0.53) | RXFP1LMNATP53MEN1KMT2A | |
| SCHEMBL24099127 | 0.76 | RXFP1 (0.61) | RXFP1LMNATP53MEN1KMT2A | |
| SCHEMBL30380730 | 0.75 | TP53 (0.68) | RXFP1LMNATP53MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264587-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | UNIV DREXEL (US) | 2016-09-15 | — | — | US | disclosed |
| US-9375474-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | DREXEL UNIVERSITY (US) | 2016-06-28 | — | — | US | disclosed |
| US-20130156761-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | Alliance Discovery, Inc. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130156761-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | CX3CR1, CCL2, CCR5 | RXFP1 188/4885LMNA 4374/4885TP53 1011/4885 |
| US-20160264587-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | CX3CR1, CCL2, CCR5 | RXFP1 188/4885LMNA 4374/4885TP53 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.